Edition:
United Kingdom

Seres Therapeutics Inc (MCRB.OQ)

MCRB.OQ on NASDAQ Stock Exchange Global Select Market

10.22USD
7:23pm GMT
Change (% chg)

$0.02 (+0.20%)
Prev Close
$10.20
Open
$10.23
Day's High
$10.27
Day's Low
$10.06
Volume
14,234
Avg. Vol
64,368
52-wk High
$17.33
52-wk Low
$8.86

Latest Key Developments (Source: Significant Developments)

Seres Therapeutics Announces FDA Orphan Drug Designation For SER-287 In Treatment Of Pediatric Ulcerative Colitis
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Seres Therapeutics Inc ::SERES THERAPEUTICS ANNOUNCES FDA ORPHAN DRUG DESIGNATION FOR SER-287 IN TREATMENT OF PEDIATRIC ULCERATIVE COLITIS.SERES THERAPEUTICS INC - SER-287 PHASE 1B MICROBIOME DATA ARE EXPECTED IN EARLY 2018.  Full Article

Seres Therapeutics Q3 net loss per share ‍$0.17​
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Seres Therapeutics Inc : :Seres Therapeutics reports third quarter 2017 financial results and provides update on operational progress.Seres Therapeutics - ‍positive results from SER-287 phase 1B study in mild-to-moderate ulcerative colitis; co to move program into further development​.Seres therapeutics Inc - ‍in early 2018, co anticipates results from SER-262 phase 1B study in primary C. Difficile infection​.Seres Therapeutics Inc qtrly net loss per share ‍$0.17​.Seres Therapeutics Inc qtrly ‍total revenue $23 million versus $13 million​.  Full Article

Seres Therapeutics announces key findings from SER-109 Phase 2 study analyses
Tuesday, 31 Jan 2017 

Seres Therapeutics Inc : Seres Therapeutics announces key findings from SER-109 Phase 2 study analyses . Seres Therapeutics Inc - FDA discussions are ongoing regarding a new, redesigned clinical study for SER-109 . Seres - misdiagnosis of C. Difficile recurrent infection in some patients, suboptimal dosing contributed to reported SER-109 Phase 2 study outcome . Seres - saw statistically significant increase in richness of commensal spore-forming bacterial species in patients treated with SER-109, versus placebo . Seres Therapeutics Inc says no issues regarding product quality or formulation were identified which would have impacted Phase 2 study results . Seres Therapeutics Inc - also assessed whether SER-109 dose impacted degree of microbiome changes observed . Seres Therapeutics - also conducted thorough and detailed investigation of potential impacts of manufacturing and formulation changes implemented in Phase 2 study .Seres - dose used in SER-109 Phase 2 study may have been suboptimal in certain patients, and may have resulted in a "less robust drug effect".  Full Article

Seres Therapeutics reports net loss of $0.70/share
Thursday, 11 Aug 2016 

Seres Therapeutics Inc: Seres Therapeutics reports second quarter financial results and provides operational progress update . Sees existing cash will enable support of operating expenses and capital expenditure requirements well into 2018 . Qtrly net loss per share $ 0.70 . Qtrly total revenue $3 million versus nil last year . Q2 earnings per share view $-0.46 -- Thomson Reuters I/B/E/S .Q2 revenue view $4.2 million -- Thomson Reuters I/B/E/S.  Full Article

Seres, Emulate collaborate to advance Emulate's intestine-chip platform
Tuesday, 12 Jul 2016 

Seres Therapeutics Inc : Company and Emulate Inc announced a new collaboration . Seres and Emulate will work to advance Emulate's intestine-chip platform, a living-tissue-based system that models human intestine .Intends to use technology to identify novel bacteria compositions with therapeutic potential.  Full Article

Seres Therapeutics CEO reports acquisition of 160,965 shares of co by exercise of options - SEC filing
Thursday, 19 May 2016 

Seres Therapeutics Inc :Seres Therapeutics CEO Roger Pomerantz reports acquisition of 160,965 shares of co by exercise of options on May 18, at price of $0.71 - SEC filing.  Full Article

Seres Therapeutics reports Q1 loss per share $0.50
Monday, 16 May 2016 

Seres Therapeutics Inc : Qtrly total revenue $2.7 million; qtrly loss per share $0.50 . Company expects to receive an additional $30 million in development milestones during 2016 . Q1 earnings per share view $-0.48, revenue view $1.3 million -- Thomson Reuters I/B/E/S .$120 million upfront payment obtained from Nestlé Health Science.  Full Article

Seres Therapeutics announces publication of positive ser-109 phase 1b/2 study results in the journal of infectious diseases
Tuesday, 9 Feb 2016 

Seres Therapeutics Inc:Announces publication of positive ser-109 phase 1b/2 study results in the journal of infectious diseases.Results showed that 87 percent patients met predefined endpoint of preventing recurrent cdi within 8 weeks after ser-109 administration.  Full Article

Seres Therapeutics Inc reports strategic collaboration with Nestlé Health Science
Monday, 11 Jan 2016 

Seres Therapeutics Inc:Announces strategic collaboration with nestlé health science for microbiome-based clostridium difficile and inflammatory bowel disease therapies in markets outside of North America.Says deal provides $120 million upfront with potential total value of over $1.9 billion.Seres expects to receive a total of $30 million in milestone payments in 2016.Says upfront payment is expected to help fund the late-stage development of seres' lead programs.  Full Article

BRIEF-Seres Therapeutics Announces FDA Orphan Drug Designation For SER-287 In Treatment Of Pediatric Ulcerative Colitis

* SERES THERAPEUTICS ANNOUNCES FDA ORPHAN DRUG DESIGNATION FOR SER-287 IN TREATMENT OF PEDIATRIC ULCERATIVE COLITIS